Search

Your search keyword '"Pokrovsky, Vadim"' showing total 174 results
Start Over Author "Pokrovsky, Vadim" Search Limiters Full Text
174 results on '"Pokrovsky, Vadim"'

3. Correction: Plyasova et al. Penetration into Cancer Cells via Clathrin-Dependent Mechanism Allows L-Asparaginase from Rhodospirillum rubrum to Inhibit Telomerase. Pharmaceuticals 2020, 13, 286

Author

Plyasova, Anna A., primary, Pokrovskaya, Marina V., additional, Lisitsyna, Olga M., additional, Pokrovsky, Vadim S., additional, Alexandrova, Svetlana S., additional, Hilal, Abdullah, additional, Sokolov, Nikolay N., additional, and Zhdanov, Dmitry D., additional

Published
2024
Full Text
View/download PDF

4. HIV-1 drug resistance among naïve patients in Armenia in 2017–2021

Author

Osadchaya, Olga A., primary, Kireev, Dmitry E., additional, Saleeva, Daria V., additional, Kirichenko, Alina A., additional, Lapovok, Ilya A., additional, Lopatukhin, Alexey E., additional, Shlykova, Anastasia V., additional, Makhmudova, Leila F., additional, Ladnaya, Natalia N., additional, Hovakimyan, Ermis M., additional, Martoyan, Siranush V., additional, Kazaryan, Hovsep K., additional, Hovsepyan, Tamara V., additional, Sargsiants, Narina K., additional, and Pokrovsky, Vadim V., additional

Published
2024
Full Text
View/download PDF

5. m6A Methylation in Regulation of Antiviral Innate Immunity

Author

Karandashov, Ivan, primary, Kachanov, Artyom, additional, Dukich, Maria, additional, Ponomareva, Natalia, additional, Brezgin, Sergey, additional, Lukashev, Alexander, additional, Pokrovsky, Vadim S., additional, Chulanov, Vladimir, additional, Kostyusheva, Anastasiya, additional, and Kostyushev, Dmitry, additional

Published
2024
Full Text
View/download PDF

8. Assessment of the effects of amphiphilic poly (N‑vinylpyrrolidone) nanoparticles loaded with bortezomib on glioblastoma cell lines and zebrafish embryos

Author

Yagolovich, Anne, primary, Kuskov, Andrey, additional, Kulikov, Pavel, additional, Bagrov, Dmitry, additional, Petrova, Polina, additional, Kukovyakina, Ekaterina, additional, Isakova, Alina, additional, Khan, Irina, additional, Pokrovsky, Vadim, additional, Nosyrev, Alexander, additional, Stamati, Polyxeni, additional, Markvicheva, Elena, additional, Gasparian, Marine, additional, Spandidos, Demetrios, additional, and Tsatsakis, Aristidis, additional

Published
2024
Full Text
View/download PDF

9. Human Metastatic Melanoma Cell Lines Panel for In Vitro and In Vivo Investigations

Author

Kosobokova, Ekaterina N., primary, Kalinina, Nadezhda A., additional, Konoplina, Ksenia M., additional, Malchenkova, Anastasiia A., additional, Evdokimova, Alexandra E., additional, Piniugina, Marina V., additional, Khan, Irina I., additional, Kislyak, Ilya A., additional, Basharina, Anna A., additional, Grishanina, Anna N., additional, Rudakova, Anna A., additional, Varaksa, Pavel O., additional, Baryshnikova, Maria A., additional, Pokrovsky, Vadim S., additional, Bogush, Tatiana A., additional, and Kosorukov, Vyacheslav S., additional

Published
2024
Full Text
View/download PDF

10. [3+2]-Cycloaddition of Nitrile Imines to Parabanic Acid Derivatives—An Approach to Novel Spiroimidazolidinediones

Author

Kuznetsova, Juliana V., primary, Tkachenko, Varvara T., additional, Petrovskaya, Lada M., additional, Filkina, Maria E., additional, Shybanov, Dmitry E., additional, Grishin, Yuri K., additional, Roznyatovsky, Vitaly A., additional, Tafeenko, Viktor A., additional, Pestretsova, Anna S., additional, Yakovleva, Vera A., additional, Pokrovsky, Vadim S., additional, Kukushkin, Maxim E., additional, and Beloglazkina, Elena K., additional

Published
2023
Full Text
View/download PDF

11. Swelling, Rupture and Endosomal Escape of Biological Nanoparticles Per Se and Those Fused with Liposomes in Acidic Environment.

Author

Ponomareva, Natalia, Brezgin, Sergey, Karandashov, Ivan, Kostyusheva, Anastasiya, Demina, Polina, Slatinskaya, Olga, Bayurova, Ekaterina, Silachev, Denis, Pokrovsky, Vadim S., Gegechkori, Vladimir, Khaydukov, Evgeny, Maksimov, Georgy, Frolova, Anastasia, Gordeychuk, Ilya, Zamyatnin Jr., Andrey A., Chulanov, Vladimir, Parodi, Alessandro, and Kostyushev, Dmitry

Subjects
LYSOSOMES, LIPOSOMES, NANOPARTICLES, NUCLEIC acids, EXTRACELLULAR vesicles, SERS spectroscopy
Abstract

Biological nanoparticles (NPs), such as extracellular vesicles (EVs), exosome-mimetic nanovesicles (EMNVs) and nanoghosts (NGs), are perspective non-viral delivery vehicles for all types of therapeutic cargo. Biological NPs are renowned for their exceptional biocompatibility and safety, alongside their ease of functionalization, but a significant challenge arises when attempting to load therapeutic payloads, such as nucleic acids (NAs). One effective strategy involves fusing biological NPs with liposomes loaded with NAs, resulting in hybrid carriers that offer the benefits of both biological NPs and the capacity for high cargo loads. Despite their unique parameters, one of the major issues of virtually any nanoformulation is the ability to escape degradation in the compartment of endosomes and lysosomes which determines the overall efficiency of nanotherapeutics. In this study, we fabricated all major types of biological and hybrid NPs and studied their response to the acidic environment observed in the endolysosomal compartment. In this study, we show that EMNVs display increased protonation and swelling relative to EVs and NGs in an acidic environment. Furthermore, the hybrid NPs exhibit an even greater response compared to EMNVs. Short-term incubation of EMNVs in acidic pH corresponding to late endosomes and lysosomes again induces protonation and swelling, whereas hybrid NPs are ruptured, resulting in the decline in their quantities. Our findings demonstrate that in an acidic environment, there is enhanced rupture and release of vesicular cargo observed in hybrid EMNVs that are fused with liposomes compared to EMNVs alone. This was confirmed through PAGE electrophoresis analysis of mCherry protein loaded into nanoparticles. In vitro analysis of NPs colocalization with lysosomes in HepG2 cells demonstrated that EMNVs mostly avoid the endolysosomal compartment, whereas hybrid NPs escape it over time. To conclude, (1) hybrid biological NPs fused with liposomes appear more efficient in the endolysosomal escape via the mechanism of proton sponge-associated scavenging of protons by NPs, influx of counterions and water, and rupture of endo/lysosomes, but (2) EMNVs are much more efficient than hybrid NPs in actually avoiding the endolysosomal compartment in human cells. These results reveal biochemical differences across four major types of biological and hybrid NPs and indicate that EMNVs are more efficient in escaping or avoiding the endolysosomal compartment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. m 6 A Methylation in Regulation of Antiviral Innate Immunity.

Author

Karandashov, Ivan, Kachanov, Artyom, Dukich, Maria, Ponomareva, Natalia, Brezgin, Sergey, Lukashev, Alexander, Pokrovsky, Vadim S., Chulanov, Vladimir, Kostyusheva, Anastasiya, and Kostyushev, Dmitry

Subjects
VIRUS diseases, NATURAL immunity, RNA modification & restriction, ANTIVIRAL agents, VIRAL replication, METHYLATION, RNA metabolism
Abstract

The epitranscriptomic modification m6A is a prevalent RNA modification that plays a crucial role in the regulation of various aspects of RNA metabolism. It has been found to be involved in a wide range of physiological processes and disease states. Of particular interest is the role of m6A machinery and modifications in viral infections, serving as an evolutionary marker for distinguishing between self and non-self entities. In this review article, we present a comprehensive overview of the epitranscriptomic modification m6A and its implications for the interplay between viruses and their host, focusing on immune responses and viral replication. We outline future research directions that highlight the role of m6A in viral nucleic acid recognition, initiation of antiviral immune responses, and modulation of antiviral signaling pathways. Additionally, we discuss the potential of m6A as a prognostic biomarker and a target for therapeutic interventions in viral infections. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Anti-Cancer Potential of Transiently Transfected HER2-Specific Human Mixed CAR-T and NK Cell Populations in Experimental Models: Initial Studies on Fucosylated Chondroitin Sulfate Usage for Safer Treatment

Author

Chikileva, Irina O., primary, Bruter, Alexandra V., additional, Persiyantseva, Nadezhda A., additional, Zamkova, Maria A., additional, Vlasenko, Raimonda Ya., additional, Dolzhikova, Yuliya I., additional, Shubina, Irina Zh., additional, Donenko, Fedor V., additional, Lebedinskaya, Olga V., additional, Sokolova, Darina V., additional, Pokrovsky, Vadim S., additional, Fedorova, Polina O., additional, Ustyuzhanina, Nadezhda E., additional, Anisimova, Natalia Yu., additional, Nifantiev, Nikolay E., additional, and Kiselevskiy, Mikhail V., additional

Published
2023
Full Text
View/download PDF

14. Upconversion Nanoparticles Intercalated in Large Polymer Micelles for Tumor Imaging and Chemo/Photothermal Therapy

Author

Demina, Polina A., primary, Khaydukov, Kirill V., additional, Babayeva, Gulalek, additional, Varaksa, Pavel O., additional, Atanova, Alexandra V., additional, Stepanov, Maxim E., additional, Nikolaeva, Maria E., additional, Krylov, Ivan V., additional, Evstratova, Irina I., additional, Pokrovsky, Vadim S., additional, Zhigarkov, Vyacheslav S., additional, Akasov, Roman A., additional, Egorova, Tatiana V., additional, Khaydukov, Evgeny V., additional, and Generalova, Alla N., additional

Published
2023
Full Text
View/download PDF

15. Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials

Author

Rizzardini, Giuliano, Overton, Edgar T., Orkin, Chloe, Swindells, Susan, Arasteh, Keikawus, Górgolas Hernández-Mora, Miguel, Pokrovsky, Vadim, Girard, Pierre-Marie, Oka, Shinichi, Andrade-Villanueva, Jaime F., Richmond, Gary J., Baumgarten, Axel, Masiá, Mar, Latiff, Gulam, Griffith, Sandy, Harrington, Conn M., Hudson, Krischan J., St. Clair, Marty, Talarico, Christine L., Patel, Parul, Cutrell, Amy, Van Eygen, Veerle, DʼAmico, Ronald, Mrus, Joseph M., Wu, Sterling, Ford, Susan L., Chow, Ken, Roberts, Jeremy, Wills, Angela, Walters, Nicola, Vanveggel, Simon, Van Solingen-Ristea, Rodica, Crauwels, Herta, Smith, Kimberly Y., Spreen, William R., and Margolis, David A.

Published
2020
Full Text
View/download PDF

16. Design, in silicostudies, synthesis, and in vitroanticancer assessment of new naphthylidene isoxazolidinedione derivatives

Author

Upadhyay, Neha, Tilekar, Kalpana, Oak, Aditi, Pokrovsky, Vadim S., and Subramanian Chelakara, Ramaa

Abstract

Cancer is the most destructive and fatal disease, representing an urgent medical challenge to the world. The discovery of a new anticancer candidate may help reduce or eliminate this alarming disease to a greater extent. On similar lines, in silico research was carried out on novel naphthylidene isoxazolidinedione derivatives that were logically conceived, synthesized, purified, and structurally characterized. In vitrobiological evaluation revealed the most active compound 4d with an inhibitory concentration of 42.87 µmagainst K562 and 47.42 µmon A549 cells. The anticancer activity of this naphthylidene isoxazolidinedione derivative was evident by cell cycle and apoptosis assays, which showed arrest of the G2/M phase (65.6%) of the K562 cells and induction of apoptosis with 21.47% apoptotic cells as compared to 0.2% of untreated cells, respectively.

Published
2024
Full Text
View/download PDF

17. [3+2]-Cycloaddition of Nitrile Imines to Parabanic Acid Derivatives—An Approach to Novel Spiroimidazolidinediones.

Author

Kuznetsova, Juliana V., Tkachenko, Varvara T., Petrovskaya, Lada M., Filkina, Maria E., Shybanov, Dmitry E., Grishin, Yuri K., Roznyatovsky, Vitaly A., Tafeenko, Viktor A., Pestretsova, Anna S., Yakovleva, Vera A., Pokrovsky, Vadim S., Kukushkin, Maxim E., and Beloglazkina, Elena K.

Subjects
NITRILIMINES, ACID derivatives, DOUBLE bonds, ELECTRON donors, TERTIARY amines, COLON cancer
Abstract

Approximately 1,3-Dipolar cycloaddition of imidazolidine derivatives containing exocyclic double bonds is a convenient method of creating spiro-conjugated molecules with promising anticancer activity. In this work, the derivatives of parabanic acid (2-thioxoimidazolidine-4,5-diones and 5-aryliminoimidazolidine-2,4-diones) were first investigated as dipolarophiles in the reactions with nitrile imines. The generation of nitrile imines was carried out either by the addition of tertiary amine to hydrazonoyl chlorides «drop by drop» or using the recently proposed diffusion mixing technique, which led to ~5–15% increases in target compound yields. It was found that the addition of nitrile imines to C=S or C=N exocyclic double bonds led to 1,2,4-thiazolines or triazolines and occurred regioselectively in accordance with the ratio of FMO coefficients of reactants. The yield of the resulting spiro-compound depended on the presence of alkyl substituents in the nitrile imine structure and was significantly decreased in reactions with imines with strong electron donor or electron-withdrawing groups. Some of the obtained compounds showed reasonable in vitro cytotoxicity. IC50 values were calculated for HCT116 (colon cancer) cells using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) test. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Toxicity Evaluation and Controlled-Release of Curcumin-Loaded Amphiphilic Poly-N-vinylpyrrolidone Nanoparticles: In Vitro and In Vivo Models.

Author

Luss, Anna L., Bagrov, Dmitry V., Yagolovich, Anne V., Kukovyakina, Ekaterina V., Khan, Irina I., Pokrovsky, Vadim S., Shestovskaya, Maria V., Gasparian, Marine E., Dolgikh, Dmitry A., and Kuskov, Andrey N.

Subjects
CURCUMIN, TOXICITY testing, SQUAMOUS cell carcinoma, NANOPARTICLES, CYTOTOXINS, NUCLEAR forces (Physics), ELECTROPHORETIC deposition
Abstract

Curcumin attracts huge attention because of its biological properties: it is antiproliferative, antioxidant, anti-inflammatory, immunomodulatory and so on. However, its usage has been limited by poor water solubility and low bioavailability. Herein, to solve these problems, we developed curcumin-loaded nanoparticles based on end-capped amphiphilic poly(N-vinylpyrrolidone). Nanoparticles were obtained using the solvent evaporation method and were characterized by dynamic and electrophoretic light scattering, transmission electron (TEM) and atomic force (AFM) microscopy. The average particle size was 200 nm, and the ζ-potential was −4 mV. Curcumin-release studies showed that nanoparticles are stable in aqueous solutions. An in vitro release study showed prolonged action in gastric, intestinal and colonic fluids, consistently, and in PBS. In vitro studies on epidermoid carcinoma and human embryonic kidney cells showed that the cells absorbed more curcumin in nanoparticles compared to free curcumin. Nanoparticles are safe for healthy cells and show high cytotoxicity for glioblastoma cells in cytotoxicity studies in vitro. The median lethal dose was determined in an acute toxicity assay on zebrafish and was 23 μM. Overall, the curcumin-loaded nanoparticles seem promising for cancer treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Expert consensus statement on the science of HIV in the context of criminal law

Author

Barre-Sinoussi, Francoise, Karim, Salim S. Abdool, Albert, Jan, Bekker, Linda-Gail, Beyrer, Chris, Cahn, Pedro, Calmy, Alexandra, Grinsztejn, Beatriz, Grulich, Andrew, Kamarulzaman, Adeeba, Kumarasamy, Nagalingeswaran, Loutfy, Mona R., Filali, Kamal M. El, Mboup, Souleymane, Montaner, Julio S.G., Munderi, Paula, Pokrovsky, Vadim, Vandamme, Anne-Mieke, Young, Benjamin, and Godfrey-Fausset, Peter

Subjects
HIV infections -- Risk factors -- Control -- Laws, regulations and rules, Disease transmission -- Control, Human rights -- Social aspects, Criminal law, Government regulation, Health
Abstract

Introduction: Globally, prosecutions for non-disclosure, exposure or transmission of HIV frequently relate to sexual activity, biting, or spitting. This includes instances in which no harm was intended, HIV transmission did not occur, and HIV transmission was extremely unlikely or not possible. This suggests prosecutions are not always guided by the best available scientific and medical evidence. Discussion: Twenty scientists from regions across the world developed this Expert Consensus Statement to address the use of HIV science by the criminal justice system. A detailed analysis of the best available scientific and medical research data on HIV transmission, treatment effectiveness and forensic phylogenetic evidence was performed and described so it may be better understood in criminal law contexts. Description of the possibility of HIV transmission was limited to acts most often at issue in criminal cases. The possibility of HIV transmission during a single, specific act was positioned along a continuum of risk, noting that the possibility of HIV transmission varies according to a range of intersecting factors including viral load, condom use, and other risk reduction practices. Current evidence suggests the possibility of HIV transmission during a single episode of sex, biting or spitting ranges from no possibility to low possibility. Further research considered the positive health impact of modern antiretroviral therapies that have improved the life expectancy of most people living with HIV to a point similar to their HIV-negative counterparts, transforming HIV infection into a chronic, manageable health condition. Lastly, consideration of the use of scientific evidence in court found that phylogenetic analysis alone cannot prove beyond reasonable doubt that one person infected another although it can be used to exonerate a defendant. Conclusions: The application of up-to-date scientific evidence in criminal cases has the potential to limit unjust prosecutions and convictions. The authors recommend that caution be exercised when considering prosecution, and encourage governments and those working in legal and judicial systems to pay close attention to the significant advances in HIV science that have occurred over the last three decades to ensure current scientific knowledge informs application of the law in cases related to HIV. Keywords: human rights; law and policy; risk factors; policy; criminalization; criminal law; prosecution, 1 | INTRODUCTION At least 68 countries have laws that specifically criminalize HIV non-disclosure, exposure, or transmission. Thirty-three countries are known to have applied other criminal law provisions in similar [...]

Published
2018
Full Text
View/download PDF

20. The Russian database of HIV antiretroviral drug resistance

Author

Kireev, Dmitry E., primary, Kirichenko, Alina A., additional, Lopatukhin, Alexey Е., additional, Shlykova, Anastasiia V., additional, Galkin, Nikolai Yu., additional, Saveler, Evgenii V., additional, Glazov, Maxim B., additional, Pokrovsky, Vadim V., additional, and Akimkin, Vasily G., additional

Published
2023
Full Text
View/download PDF

22. HIV-1 Drug Resistance among Treatment-Naïve Patients in Russia: Analysis of the National Database, 2006–2022

Author

Kirichenko, Alina, primary, Kireev, Dmitry, additional, Lapovok, Ilya, additional, Shlykova, Anastasia, additional, Lopatukhin, Alexey, additional, Pokrovskaya, Anastasia, additional, Bobkova, Marina, additional, Antonova, Anastasiia, additional, Kuznetsova, Anna, additional, Ozhmegova, Ekaterina, additional, Shtrek, Sergey, additional, Sannikov, Aleksej, additional, Zaytseva, Natalia, additional, Peksheva, Olga, additional, Piterskiy, Michael, additional, Semenov, Aleksandr, additional, Turbina, Galina, additional, Filoniuk, Natalia, additional, Shemshura, Andrey, additional, Kulagin, Valeriy, additional, Kolpakov, Dmitry, additional, Suladze, Aleksandr, additional, Kotova, Valeriya, additional, Balakhontseva, Lyudmila, additional, Pokrovsky, Vadim, additional, and Akimkin, Vasiliy, additional

Published
2023
Full Text
View/download PDF

23. Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial

Author

Kityo, Cissy, Hagins, Debbie, Koenig, Ellen, Avihingsanon, Anchalee, Chetchotisakd, Ploenchan, Supparatpinyo, Khuanchai, Gankina, Natalya, Pokrovsky, Vadim, Voronin, Evgeny, Stephens, Jeffrey L., DeJesus, Edwin, Wang, Hui, Acosta, Rima K., Cao, Huyen, Quirk, Erin, Martin, Hal, and Makadzange, Tariro

Published
2019
Full Text
View/download PDF

24. Synthesis and Biological Evaluation of Benzo [4,5]- and Naphtho[2′,1′:4,5]imidazo[1,2-c]pyrimidinone Derivatives.

Author

Kamzeeva, Polina, Dagaev, Nikolai, Lizunova, Sofia, Khodarovich, Yuri, Sogomonyan, Anna, Kolchanova, Anastasia, Pokrovsky, Vadim, Alferova, Vera, Chistov, Alexey, Eshtukov-Shcheglov, Artur, Eshtukova-Shcheglova, Elizaveta, Belyaev, Evgeny, Skvortsov, Dmitry, Varizhuk, Anna, and Aralov, Andrey

Subjects
BIOSYNTHESIS, POISONS, IMIDAZOPYRIDINES, DRUG target, BODY weight, ANTINEOPLASTIC agents, ONCOGENES
Abstract

Azacarbazoles have attracted significant interest due to their valuable properties, such as anti-pathogenic and antitumor activity. In this study, a series of structurally related tricyclic benzo[4,5]- and tertacyclic naphtho[2′,1′:4,5]imidazo[1,2-c]pyrimidinone derivatives with one or two positively charged tethers were synthesized and evaluated for anti-proliferative activity. Lead tetracyclic derivative 5b with two amino-bearing arms inhibited the metabolic activity of A549 lung adenocarcinoma cells with a CC50 value of 3.6 μM, with remarkable selectivity (SI = 17.3) over VA13 immortalized fibroblasts. Cell-cycle assays revealed that 5b triggers G2/M arrest without signs of apoptosis. A study of its interaction with various DNA G4s and duplexes followed by dual luciferase and intercalator displacement assays suggests that intercalation, rather than the modulation of G4-regulated oncogene expression, might contribute to the observed activity. Finally, a water-soluble salt of 5b was shown to cause no acute toxic effects, changes in mice behavior, or any decrease in body weight after a 72 h treatment at concentrations up to 20 mg/kg. Thus, 5b is a promising candidate for studies in vivo; however, further investigations are needed to elucidate its molecular target(s). [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

25. Synthesis and Preclinical Evaluation of Small-Molecule Prostate-Specific Membrane Antigen-Targeted Abiraterone Conjugate

Author

Machulkin, Aleksei E., primary, Nimenko, Ekaterina A., additional, Zyk, Nikolay U., additional, Uspenskaia, Anastasiia A., additional, Smirnova, Galina B., additional, Khan, Irina I., additional, Pokrovsky, Vadim S., additional, Vaneev, Alexander N., additional, Timoshenko, Roman V., additional, Mamed-Nabizade, Vugara V., additional, Zavertkina, Maria V., additional, Erofeev, Alexander, additional, Gorelkin, Petr, additional, Majouga, Alexander G., additional, Zyk, Nikolay V., additional, Khazanova, Elena S., additional, and Beloglazkina, Elena K., additional

Published
2022
Full Text
View/download PDF

26. Albumin-Functionalized Iron Oxide Nanoparticles for Theranostics: Engineering and Long-Term In Situ Imaging

Author

Bychkova, Anna V., primary, Yakunina, Marina N., additional, Lopukhova, Mariia V., additional, Degtyarev, Yevgeniy N., additional, Motyakin, Mikhail V., additional, Pokrovsky, Vadim S., additional, Kovarski, Alexander L., additional, Gorobets, Maria G., additional, Retivov, Vasily M., additional, and Khachatryan, Derenik S., additional

Published
2022
Full Text
View/download PDF

28. Prevalence of Pretreatment HIV-1 Drug Resistance in Armenia in 2017–2018 and 2020–2021 following a WHO Survey

Author

Kirichenko, Alina, primary, Kireev, Dmitry, additional, Lapovok, Ilya, additional, Shlykova, Anastasia, additional, Lopatukhin, Alexey, additional, Pokrovskaya, Anastasia, additional, Ladnaya, Natalya, additional, Grigoryan, Trdat, additional, Petrosyan, Arshak, additional, Sarhatyan, Tatevik, additional, Sargsyants, Narina, additional, Hovsepyan, Tamara, additional, Ghazaryan, Hovsep, additional, Hovakimyan, Hermine, additional, Martoyan, Siranush, additional, and Pokrovsky, Vadim, additional

Published
2022
Full Text
View/download PDF

29. Chlorin e6 Phospholipid Delivery System Featuring APN/CD13 Targeting Peptides: Cell Death Pathways, Cell Localization, In Vivo Biodistribution

Author

Tereshkina, Yulia A., primary, Kostryukova, Lyubov V., additional, Tikhonova, Elena G., additional, Khudoklinova, Yulia Yu., additional, Orlova, Nadezhda A., additional, Gisina, Alisa M., additional, Morozevich, Galina E., additional, Melnikov, Pavel A., additional, and Pokrovsky, Vadim S., additional

Published
2022
Full Text
View/download PDF

30. Cell models with inducible oncogenic translocations allow to evaluate the potential of drugs to favor secondary translocations

Author

Shmakova, Anna, primary, Lomov, Nikolai, additional, Viushkov, Vladimir, additional, Tsfasman, Tatyana, additional, Kozhevnikova, Yana, additional, Sokolova, Darina, additional, Pokrovsky, Vadim, additional, Syrkina, Marina, additional, Germini, Diego, additional, Rubtsov, Mikhail, additional, and Vassetzky, Yegor, additional

Published
2022
Full Text
View/download PDF

34. In Silico, In Vitro, and Clinical Investigations of Cathepsin B and Stefin A mRNA Expression and a Correlation Analysis in Kidney Cancer

Author

Rudzinska-Radecka, Magdalena, primary, Frolova, Anastasia S., additional, Balakireva, Anastasia V., additional, Gorokhovets, Neonila V., additional, Pokrovsky, Vadim S., additional, Sokolova, Darina V., additional, Korolev, Dmitry O., additional, Potoldykova, Natalia V., additional, Vinarov, Andrey Z., additional, Parodi, Alessandro, additional, and Zamyatnin, Andrey A., additional

Published
2022
Full Text
View/download PDF

36. Prevalence of HIV-1 drug resistance in Eastern European and Central Asian countries

Author

Kirichenko, Alina, primary, Kireev, Dmitry, additional, Lopatukhin, Alexey, additional, Murzakova, Anastasia, additional, Lapovok, Ilya, additional, Saleeva, Daria, additional, Ladnaya, Natalya, additional, Gadirova, Agigat, additional, Ibrahimova, Sabina, additional, Safarova, Aygun, additional, Grigoryan, Trdat, additional, Petrosyan, Arshak, additional, Sarhatyan, Tatevik, additional, Gasich, Elena, additional, Bunas, Anastasia, additional, Glinskaya, Iryna, additional, Yurovsky, Pavel, additional, Nurov, Rustam, additional, Soliev, Alijon, additional, Ismatova, Laylo, additional, Musabaev, Erkin, additional, Kazakova, Evgeniya, additional, Rakhimova, Visola, additional, and Pokrovsky, Vadim, additional

Published
2022
Full Text
View/download PDF

37. Molecular epidemiology of HIV-1 in Oryol Oblast, Russia

Author

Safina, Ksenia R, primary, Sidorina, Yulia, additional, Efendieva, Natalya, additional, Belonosova, Elena, additional, Saleeva, Darya, additional, Kirichenko, Alina, additional, Kireev, Dmitry, additional, Pokrovsky, Vadim, additional, and Bazykin, Georgii A, additional

Published
2022
Full Text
View/download PDF

42. Elbasvir/Grazoprevir for HCV Infection in Russia: A Randomized Trial

Author

Zhdanov, Konstantin, Isakov, Vasily, Burnevich, Eduard, Kizhlo, Svetlana, Bakulin, Igor, Pokrovsky, Vadim, Liang, Liwen, Hwang, Peggy, Talwani, Rohit, Haber, Barbara A, and Robertson, Michael N

Subjects
therapy, placebo, virus diseases, hepatitis C, viral drug resistance, Evidence and Research [Hepatic Medicine], Original Research, Russia
Abstract

Konstantin Zhdanov,1 Vasily Isakov,2 Eduard Burnevich,3 Svetlana Kizhlo,4 Igor Bakulin,5 Vadim Pokrovsky,6 Liwen Liang,7 Peggy Hwang,7 Rohit Talwani,7 Barbara A Haber,7 Michael N Robertson7 1Military Medical Academy n.a. S.M. Kirov, St. Petersburg, Russia; 2Department of Gastroenterology & Hepatology, Federal Research Centre of Nutrition, Biotechnology and Food Safety, Moscow, Russia; 3I.M. Sechenov First Moscow State Medical University, Moscow, Russia; 4City Center for AIDS and Infectious Diseases Treatment and Prophylaxis, St. Petersburg, Russia; 5I.I. Mechnikov North-Western State Medical University of the Ministry of Health of the Russian Federation, St. Petersburg, Russia; 6Department of AIDS, Central Research Institute of Epidemiology, Moscow, Russia; 7Merck & Co., Inc., Kenilworth, NJ, USACorrespondence: Barbara A HaberMerck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USATel +1 267-305-3729Email barbara.haber@merck.comPurpose: Hepatitis C virus (HCV) infection is a major healthcare concern in Russia, where almost 5 million individuals are viremic. Elbasvir/grazoprevir is a fixed-dose combination therapy for the treatment of HCV genotype 1 and genotype 4 infection. The present analysis aimed to assess the safety and efficacy of elbasvir/grazoprevir in individuals with HCV infection enrolled at Russian study sites in the C-CORAL study.Patients and Methods: C-CORAL (Protocol PN-5172-067; NCT02251990) was a Phase 3, placebo-controlled, double-blind study conducted throughout Asia and Russia. Treatment-naive participants with chronic HCV infection were randomly assigned to receive immediate or deferred treatment with elbasvir 50 mg/grazoprevir 100 mg once daily for 12 weeks. Participants in the immediate-treatment group received elbasvir/grazoprevir for 12 weeks, and those in the deferred-treatment group received placebo for 12 weeks, followed by open-label elbasvir/grazoprevir for 12 weeks. The primary endpoint was sustained virologic response at 12 weeks after completion of therapy (SVR12).Results: One hundred and nineteen Russian participants were randomized (immediate-treatment group, n=88; deferred-treatment group, n=31). Most participants were white (99%) with HCV genotype 1b infection (97%) and mild-to-moderate (F0–F2) fibrosis (70%). SVR12 was achieved by 98.9% participants in the immediate-treatment group and by 100% of those receiving deferred elbasvir/grazoprevir in the deferred-treatment group. One participant relapsed with nonstructural protein 5A (NS5A) L28M and Y93H resistance-associated substitutions at baseline and at time of failure. Drug-related adverse events were reported by 19% of participants receiving elbasvir/grazoprevir in the immediate-treatment group and by 16% of those receiving placebo in the deferred-treatment group. No serious adverse event or deaths occurred, and no participant discontinued treatment owing to an adverse event.Conclusion: Elbasvir/grazoprevir for 12 weeks was highly effective in treatment-naive Russian individuals with HCV genotype 1b infection.Keywords: hepatitis C, therapy, placebo, Russia, viral drug resistance

Published
2020

43. Elbasvir/Grazoprevir for HCV Infection in Russia: A Randomized Trial

Author

Zhdanov,Konstantin, Isakov,Vasily, Burnevich,Eduard, Kizhlo,Svetlana, Bakulin,Igor, Pokrovsky,Vadim, Liang,Liwen, Hwang,Peggy, Talwani,Rohit, Haber,Barbara A, Robertson,Michael, Zhdanov,Konstantin, Isakov,Vasily, Burnevich,Eduard, Kizhlo,Svetlana, Bakulin,Igor, Pokrovsky,Vadim, Liang,Liwen, Hwang,Peggy, Talwani,Rohit, Haber,Barbara A, and Robertson,Michael

Abstract

Konstantin Zhdanov,1 Vasily Isakov,2 Eduard Burnevich,3 Svetlana Kizhlo,4 Igor Bakulin,5 Vadim Pokrovsky,6 Liwen Liang,7 Peggy Hwang,7 Rohit Talwani,7 Barbara A Haber,7 Michael N Robertson7 1Military Medical Academy n.a. S.M. Kirov, St. Petersburg, Russia; 2Department of Gastroenterology & Hepatology, Federal Research Centre of Nutrition, Biotechnology and Food Safety, Moscow, Russia; 3I.M. Sechenov First Moscow State Medical University, Moscow, Russia; 4City Center for AIDS and Infectious Diseases Treatment and Prophylaxis, St. Petersburg, Russia; 5I.I. Mechnikov North-Western State Medical University of the Ministry of Health of the Russian Federation, St. Petersburg, Russia; 6Department of AIDS, Central Research Institute of Epidemiology, Moscow, Russia; 7Merck & Co., Inc., Kenilworth, NJ, USACorrespondence: Barbara A HaberMerck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USATel +1 267-305-3729Email barbara.haber@merck.comPurpose: Hepatitis C virus (HCV) infection is a major healthcare concern in Russia, where almost 5 million individuals are viremic. Elbasvir/grazoprevir is a fixed-dose combination therapy for the treatment of HCV genotype 1 and genotype 4 infection. The present analysis aimed to assess the safety and efficacy of elbasvir/grazoprevir in individuals with HCV infection enrolled at Russian study sites in the C-CORAL study.Patients and Methods: C-CORAL (Protocol PN-5172-067; NCT02251990) was a Phase 3, placebo-controlled, double-blind study conducted throughout Asia and Russia. Treatment-naive participants with chronic HCV infection were randomly assigned to receive immediate or deferred treatment with elbasvir 50 mg/grazoprevir 100 mg once daily for 12 weeks. Participants in the immediate-treatment group received elbasvir/grazoprevir for 12 weeks, and those in the deferred-treatment group received placebo for 12 weeks, followed by open-label elbasvir/grazoprevir for 12 weeks. The primary endpoint was sustain

Published
2020

46. Multicomponent nutritional supplement Oncoxin and its influence on quality of life and therapy toxicity in patients receiving adjuvant chemotherapy

Author

Kaidarova, Dilyara, primary, Kopp, Mikhail, additional, Pokrovsky, Vadim, additional, Dzhugashvili, Мaia, additional, Akimzhanova, Zhanna, additional, Abdrakhmanov, Ramil, additional, Babich, Elena, additional, Bilan, Evgeniy, additional, Byakhov, Anton, additional, Gurov, Sergey, additional, Koroleva, Irina, additional, Mochalova, Anastasiia, additional, Povaga, Svetlana, additional, Raigorodsky, Maxim, additional, Saifullin, Arthur, additional, Sanz, Eduardo, additional, and Petrovskiy, Fedor, additional

Published
2019
Full Text
View/download PDF

47. Molecular Epidemiology of HIV-1 Subtype G in the Russian Federation

Author

Murzakova, Anastasia, primary, Kireev, Dmitry, additional, Baryshev, Pavel, additional, Lopatukhin, Alexey, additional, Serova, Ekaterina, additional, Shemshura, Andrey, additional, Saukhat, Sergey, additional, Kolpakov, Dmitry, additional, Matuzkova, Anna, additional, Suladze, Alexander, additional, Nosik, Marina, additional, Eremin, Vladimir, additional, Shipulin, German, additional, and Pokrovsky, Vadim, additional

Published
2019
Full Text
View/download PDF

48. Clinical significance of HIV DNA in polymorphonuclear neutrophils from patients with HIV infection

Author

Gabrilovich, Dmitry I., Vassilev, Ventzislav, Nosikov, Valery V., Serebrovskaya, Lidia V., Ivanova, Larisa A., and Pokrovsky, Vadim V.

Subjects
Neutrophils -- Physiological aspects, HIV (Viruses) -- Genetic aspects, Pneumocystis carinii pneumonia -- Physiological aspects, Neutropenia -- Health aspects, Health
Abstract

DNA from the human immunodeficiency virus (HIV) was detected in the neutrophils of HIV-infected patients. Neutrophils are cells which play a part in immune responses. The breakdown of neutrophil activity is part of the process of infection with HIV. This decrease in functioning may play a role in the susceptibility of AIDS patients to diseases. Neutrophils were isolated from blood samples from 37 HIV-infected patients. HIV DNA was most often found in the neutrophils of patients who had symptoms of HIV infection. HIV DNA was found more often in patients with low blood levels of neutrophils. HIV DNA was also found more often in patients with Pneumocystis carinii pneumonia.

Published
1993

Catalog

Books, media, physical & digital resources
See catalog results